Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

1. WO2005002627 - INHIBITEURS DE LA CASCADE DE COMPLEMENTS CONJUGUES

Numéro de publication WO/2005/002627
Date de publication 13.01.2005
N° de la demande internationale PCT/US2004/019457
Date du dépôt international 18.06.2004
Demande présentée en vertu du Chapitre 2 02.02.2005
CIB
A61K 47/48 2006.01
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
47Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif
48l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
CPC
A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61K 47/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61K 47/60
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
59obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
60the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 11/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
Déposants
  • ORTHO-MCNEIL PHARMACEUTICAL, INC. [US/US]; U.S. Route #202 P.O. Box 300 Raritan, NJ 08869-0602, US (AllExceptUS)
  • SUBASINGHE, Nalin [US/US]; US (UsOnly)
  • Khalil, Ehab [US/US]; US (UsOnly)
  • ALI, Farah [US/US]; US (UsOnly)
  • HUFNAGEL, Heather, Rae [US/US]; US (UsOnly)
  • BALLENTINE, Shelley, K. [US/US]; US (UsOnly)
  • TRAVINS, Jeremy, M. [US/US]; US (UsOnly)
  • LEONARD, Kristi, A. [US/US]; US (UsOnly)
  • BONE, Roger, F. [US/US]; US (UsOnly)
Inventeurs
  • SUBASINGHE, Nalin; US
  • Khalil, Ehab; US
  • ALI, Farah; US
  • HUFNAGEL, Heather, Rae; US
  • BALLENTINE, Shelley, K.; US
  • TRAVINS, Jeremy, M.; US
  • LEONARD, Kristi, A.; US
  • BONE, Roger, F.; US
Mandataires
  • JOHNSON, Philip, S.; Johnson & Johnson ONe Johnson & Johnson Plaza New Brunswick, NJ 08933, US
Données relatives à la priorité
10/869,43016.06.2004US
60/484,85403.07.2003US
60/571,37414.05.2004US
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) CONJUGATED COMPLEMENT CASCADE INHIBITORS
(FR) INHIBITEURS DE LA CASCADE DE COMPLEMENTS CONJUGUES
Abrégé
(EN)
The present invention is directed to conjugated complement cascade inhibitors, and a method of treating a patient using a conjugated complement cascade inhibitor. The present invention is directed, in part, to compounds comprising a conjugated complement cascade inhibitor. The compounds may advantageously bind to a receptor in a component of the complement cascade, and may thereby inhibit the complement cascade or inhibit the effects of the proteins which are formed from the cascade (for example C3a and C5a). In one embodiment, the present invention provides a pharmaceutical for treating a patient, comprising a conjugated complement inhibitor. In another embodiment, the present invention provides a method of treating a patient to suppress activation of the complement cascade, comprising administering a conjugated complement inhibitor to the patient. These and other aspects of the invention will become more apparent from the present description and claims.
(FR)
Cette invention concerne des inhibiteurs de la cascade de compléments conjugués, et sur un procédé de traitement d'un patient au moyen d'un inhibiteur de la cascade de compléments conjugués.
Également publié en tant que
EP2011001623
HRP20060007A
IN63/KOLNP/2006
NZ544407
Dernières données bibliographiques dont dispose le Bureau international